These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17846598)

  • 1. Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL).
    Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK; Leung N; Gastineau DA
    Bone Marrow Transplant; 2007 Nov; 40(10):989-93. PubMed ID: 17846598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization.
    Gertz MA; Gastineau DA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK; Dingli D; Leung N; Wolf RC; Hogan WJ; Buadi FK
    Bone Marrow Transplant; 2011 Jul; 46(7):956-61. PubMed ID: 20972466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
    Oran B; Malek K; Sanchorawala V; Wright DG; Quillen K; Finn KT; La Valley M; Skinner M; Seldin DC
    Bone Marrow Transplant; 2005 Mar; 35(6):567-75. PubMed ID: 15665842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Starting granulocyte-colony-stimulating factor (filgrastim) early after autologous peripheral blood progenitor cell transplantation leads to faster engraftment without increased resource utilization.
    Thompson JM; Carlton P; Akard LP; Dugan MJ; Jansen J
    Transfusion; 2009 Mar; 49(3):548-54. PubMed ID: 19040494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD34+ cell responsiveness to stromal cell-derived factor-1alpha underlies rate of engraftment after peripheral blood stem cell transplantation.
    Marquez-Curtis LA; Turner AR; Larratt LM; Letcher B; Lee SF; Janowska-Wieczorek A
    Transfusion; 2009 Jan; 49(1):161-9. PubMed ID: 18954402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
    Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis.
    Kumar S; Dispenzieri A; Lacy MQ; Litzow MR; Gertz MA
    Bone Marrow Transplant; 2001 Aug; 28(4):381-5. PubMed ID: 11571511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders.
    Olivieri A; Scortechini I; Capelli D; Montanari M; Lucesole M; Gini G; Troiani M; Offidani M; Poloni A; Masia MC; Raggetti GM; Leoni P
    Bone Marrow Transplant; 2004 Oct; 34(8):693-702. PubMed ID: 15300235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
    Lacy MQ; Dispenzieri A; Hayman SR; Kumar S; Kyle RA; Rajkumar SV; Edwards BS; Rodeheffer RJ; Frantz RP; Kushwaha SS; Clavell AL; Dearani JA; Sundt TM; Daly RC; McGregor CG; Gastineau DA; Litzow MR; Gertz MA
    J Heart Lung Transplant; 2008 Aug; 27(8):823-9. PubMed ID: 18656793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
    Fernández de Larrea C; Cibeira MT; Rovira M; Rosiñol L; Esteve J; Bladé J
    Eur J Haematol; 2008 Feb; 80(2):182-4. PubMed ID: 18081703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
    Wildes TM; Augustin KM; Sempek D; Zhang QJ; Vij R; Dipersio JF; Devine SM
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):840-6. PubMed ID: 18541205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.
    Musto P; Scalzulli PR; Terruzzi E; Rossini F; Iacopino P; Messina G; Guariglia R; Pietrantuono G; Villani O; D'Auria F; Falcone A; Sanpaolo G; Valvano MR; Pogliani EM; Morabito F
    Leuk Res; 2007 Nov; 31(11):1487-93. PubMed ID: 17320951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
    Klabusay M; Lysák D; Hrabcáková V; Navrátil M; Coupek P; Mayer J
    Cas Lek Cesk; 2008; 147(6):319-24. PubMed ID: 18724529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
    Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients.
    Schmid I; Stachel D; Pagel P; Albert MH
    Biol Blood Marrow Transplant; 2008 Apr; 14(4):438-44. PubMed ID: 18342786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing engraftment in autologous peripheral stem cell transplantation. The experience of a local Kuwaiti transplantation center.
    Alshemmari SH; Ameen RM; Gyrafas J; Alqallaf DA; Sajnani KP
    Saudi Med J; 2007 Jul; 28(7):1080-5. PubMed ID: 17603716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.